Table 2.

Diagnostic tests and treatments used.

	Total	Confirmed COVID-19	Unconfirmed COVID-19	P
Patients, n (%)	72 (100%)	40 (55.5%)	32 (44.5%)
Chest X-ray, n (%)
Normal
Interstitial infiltrates	19 (26.4%)	10 (25%)	9 (28.1%)	a
Unilateral pneumonia	28 (38.9%)	15 (37.5%)	13 (40.6%)
Bilateral pneumonia	10 (13.9%)	6 (15%)	4 (12.5%)
Not performed	6 (8.3%)	2 (5%)	4 (12.5%)
	9 (12.5%)	7 (17.5%)	2 (6.3%)
Blood tests; median (IQR)
Lymphocytes (cells/mm3)	2260 (1445−3422.5)	1880 (1000−3360)	2410 (1750−3610)	.390
D-dimer (ng/mL)	725 (442.5−1387)	844 (639−1612.3)	620 (390−1040)	.064
LDH (IU/L)	304 (271−385)	345 (285−404)	284 (270.3−311.8)	.038
Ferritin (ng/mL)	62.5 (39.3−143.3)	112 (38.8−571.5)	45.5 (38−126.8)	.274
CRP (mg/L)	7.45 (0.5−41.8)	7.45 (0.6−56.45)	9.6 (0.5−41.6)	.363
PCT (ng/mL)	0.09 (0.05−0.15)	0.11 (0.07−0.18)	0.05 (0.03−0.11)	.018
Lymphopenia, n (%)	20 (32.3%)	14 (40%)	6 (22.2%)	.176
Oxygen therapy, n (%)
No
Nasal prongs	56 (77.8%)	28 (70%)	28 (87.5%)	.093
Reservoir	16 (22.2%)	12 (30%)	4 (12.5%)	.093
High-flow oxygen therapy	3 (4.2%)	3 (7.5%)	0	.249
NIVb	1 (1.4%)	1 (2.5%)	0	1.000
	1 (1.4%)	1 (2.5%)	0	1.000
Treatment, n (%)
Antiviral
Hydroxychloroquine	36 (50%)	24 (60%)	12 (37.5%)	.096
Lopinavir/ritonavir	1 (1.4%)	1 (2.5%)	0	1.000
Remdesivir	1 (1.4%)	1 (2.5%)	0	1.000
Antibiotic
Azithromycin	17 (23.6%)	9 (22.5%)	8 (25%)	1.000
Other antibiotics	32 (44.4%)	21 (52.5%)	11 (34.4%)	.155
Immunomodulator
Tocilizumab	2 (2.8%)	2 (5%)	0	.499
Corticosteroid	1 (1.4%)	1 (2.5%)	0	1.000
Immunoglobulin	1 (1.4%)	1 (2.5%)	0	1.000
Antiaggregant
Acetylsalicylic acid	1 (1.4%)	1 (2.5%)	0	1.000

CRP, C-reactive protein; IQR, interquartile range; LDH, lactate dehydrogenase; NIV, non-invasive mechanical ventilation; PCT, procalcitonin; COVID-19, coronavirus disease caused by SARS-CoV-2.

^aFisher exact test not applicable, variable with more than 2 categories.